Enhancing Everyday Autonomy for People With Dementia
Primary Purpose
Dementia
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Clinician-facilitated educational intervention
Enhanced usual care
Sponsored by
About this trial
This is an interventional treatment trial for Dementia
Eligibility Criteria
Inclusion Criteria:
- Individuals who are 55 years or older with a diagnosis of MCI (mild cognitive impairment) or mild to moderate dementia will be eligible (Montreal Cognitive Assessment Score, MoCA, > 10).
- Evidence of neuropsychiatric symptoms of dementia (NPI-Q score > 1).
- People with cognitive impairment must have an identified care partner: a family member, close friend, or caregiver who knows the person well with contact at least three times/week.
Exclusion Criteria:
- None.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Clinician-facilitated educational intervention
Enhanced usual care
Arm Description
Outcomes
Primary Outcome Measures
NPI-Q
Change in Neuropsychiatric Inventory brief questionnaire form (NPI-Q). The NPI-Q measures the burden of 12 neuropsychiatric symptoms of dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, and appetite/eating. Symptom severity is rated on a 3-point scale with higher scores indicating worse symptoms. Minimum score would be 0 and maximum score would be 36.
Secondary Outcome Measures
NPI-Q, caregiver distress
Change in Neuropsychiatric Inventory brief questionnaire form (NPI-Q) caregiver distress. The NPI-Q measures the caregiver distress of 12 neuropsychiatric symptoms of dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, and appetite/eating. Symptom severity is rated on a 5-point scale with higher scores indicating worse symptoms. Minimum score would be 0 and maximum score would be 60.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03577418
Brief Title
Enhancing Everyday Autonomy for People With Dementia
Official Title
Enhancing Everyday Autonomy as a Means to Reduce the Neuropsychiatric Symptoms of Dementia
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Withdrawn
Why Stopped
study never started, was not funded
Study Start Date
September 2022 (Anticipated)
Primary Completion Date
September 2025 (Anticipated)
Study Completion Date
September 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mclean Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Dementia is a highly disabling major neurocognitive disorder. Although cognitive symptoms drive the diagnosis of dementia, neuropsychiatric symptoms (NPS), such as agitation, aggression, and psychosis, are common and associated with increased morbidity/mortality, increased care partner distress, and earlier institutionalization. Although these symptoms are debilitating and experienced by more than 90% of people with dementia, there are currently no FDA-approved treatments. There remains a critical need for safe and effective interventions for NPS that can be easily administered and monitored in typical clinical settings.
One hypothesis for the etiology of NPS is that, as cognitive impairment progresses, there is a decline in the sense of autonomy and an increase in unmet needs that a person with dementia (PWD) is unable to meet on his/her own and that care partners lack the knowledge or ability to meet. As care partners become increasingly involved as surrogate decision-makers for a PWD, the quality of life for a PWD is directly impacted by the decisions made by a surrogate. Several studies have explored agreement between PWDs and surrogate decision-makers regarding various preferences. Results have indicated that discrepancy between a PWD's preferences and those identified by a surrogate decision-maker is common.
According to our conceptual model, such discrepancy may give rise to NPS. Thus, the proposed pilot project directly addresses major gaps in the availability of safe, effective, and accessible strategies to reduce NPS and NPS-related care partner distress by developing and testing a novel educational intervention that directly targets discrepancies regarding everyday preferences. We will randomize 30 dyads comprising people with clinically significant cognitive impairment (mild cognitive impairment or dementia) and their care partners. The dyads will be randomized to either 1) the intervention arm in which there is a clinician-facilitated discussion between the dyad pair about NPS, the unmet needs hypothesis, and areas of discrepancy in everyday preferences and 2) the enhanced usual care arm in which a standardized document describing NPS and the unmet needs hypothesis will be given to the dyad to review. Primary efficacy will be measured by the Neuropsychiatric Inventory brief questionnaire form (NPI-Q), which allows for assessment of both NPS burden as well as burden of caregiver stress. Assessments will be made at baseline, week 4, and week 8.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Clinician-facilitated educational intervention
Arm Type
Experimental
Arm Title
Enhanced usual care
Arm Type
Active Comparator
Intervention Type
Behavioral
Intervention Name(s)
Clinician-facilitated educational intervention
Intervention Description
People with dementia (PWD) will complete the Preferences for Everyday Living (PELI). Care partners will complete the PELI from the perspective of the PWD (i.e., as if acting as surrogate decision-makers). Research staff will then review these assessments, highlighting areas of discrepancy in the importance of various preferences. A 30-minute preferences-based discussion will then be facilitated by the research clinician. This discussion will include review of the discrepancies identified in the assessments. The PWD and the care partners will then be encouraged to identify one area of discrepancy and to come together with a concrete action plan to resolve that area of discrepancy. A standardized document describing neuropsychiatric symptoms and reviewing the unmet needs hypothesis will be discussed with PWD and the care partners.
Intervention Type
Behavioral
Intervention Name(s)
Enhanced usual care
Intervention Description
In addition to the usual clinical care, the standardized document describing NPS and reviewing the unmet needs hypothesis will be given to the PWD and the care partner to review.
Primary Outcome Measure Information:
Title
NPI-Q
Description
Change in Neuropsychiatric Inventory brief questionnaire form (NPI-Q). The NPI-Q measures the burden of 12 neuropsychiatric symptoms of dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, and appetite/eating. Symptom severity is rated on a 3-point scale with higher scores indicating worse symptoms. Minimum score would be 0 and maximum score would be 36.
Time Frame
4 weeks, 8 weeks
Secondary Outcome Measure Information:
Title
NPI-Q, caregiver distress
Description
Change in Neuropsychiatric Inventory brief questionnaire form (NPI-Q) caregiver distress. The NPI-Q measures the caregiver distress of 12 neuropsychiatric symptoms of dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, and appetite/eating. Symptom severity is rated on a 5-point scale with higher scores indicating worse symptoms. Minimum score would be 0 and maximum score would be 60.
Time Frame
4 weeks, 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Individuals who are 55 years or older with a diagnosis of MCI (mild cognitive impairment) or mild to moderate dementia will be eligible (Montreal Cognitive Assessment Score, MoCA, > 10).
Evidence of neuropsychiatric symptoms of dementia (NPI-Q score > 1).
People with cognitive impairment must have an identified care partner: a family member, close friend, or caregiver who knows the person well with contact at least three times/week.
Exclusion Criteria:
None.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Wilkins, MD, DPhil
Organizational Affiliation
Mclean Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Enhancing Everyday Autonomy for People With Dementia
We'll reach out to this number within 24 hrs